Disclosed content
Newsroom
This section carries announcements, paid releases, and sponsored features. It is deliberately separated from NSH reporting, and every item states what it is.
Information supplied by an organization about itself. Published under disclosure and not independently verified unless stated.
Paid placement of an organization's own release. NSH does not edit substance and makes no claim about accuracy.
Paid content written or reviewed by a sponsor. Not produced by the NSH editorial desk and not evidence reviewed.
- Company Announcement
FDA Grants Accelerated Approval to Camizestrant for Adults
The agency approved the estrogen receptor antagonist for use in combination with a CDK4/6 inhibitor.
October 14, 2026
- Company Announcement
FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC
The agency approved the kinase inhibitor for adult patients with locally advanced or metastatic disease.
September 15, 2026
To submit an announcement or inquire about press release services, write to nextstandardhealth@gmail.com.